Fermenta Biotech Revenue Jumps 26% in FY26, Declares ₹3.75 Dividend

Fermenta Biotech Reports Strong Operational Growth in FY26

Fermenta Biotech posted consolidated revenue of ₹538.4 crore, a 26% increase year-over-year, and consolidated EBITDA of ₹120.0 crore, up 44% year-over-year, for FY26, excluding real estate impacts.

Key Financials and Shareholder Returns

Fermenta Biotech announced its FY26 financial results, showing strong operational momentum. Consolidated revenue, excluding real estate, rose 26% to ₹538.4 crore. The company's consolidated EBITDA, also excluding real estate, surged 44% to ₹120.0 crore. Profit After Tax (PAT) decreased by 8% to ₹70.3 crore. Fermenta Biotech attributes this PAT decline to a high base effect from FY25, which included significant one-time income from real estate value unlocking. The board has recommended a dividend of ₹3.75 per share.

Business Performance and Market Demand

The robust growth in operational EBITDA highlights the underlying strength of the business and improvements in efficiency. Revenue growth in key areas like Vitamin D3 for human and animal nutrition indicates steady market demand. The significant revenue increase in Green Chemistry Solutions points to successful expansion into new, high-growth markets.

However, investors should note the PAT decline, though explained by the base effect. A reduction in average realization for animal nutrition and a wider loss in the US trading subsidiary also warrant attention.

Financial Context from Previous Year

In FY25, Fermenta Biotech's PAT was boosted by ₹44.6 crore from one-time real estate income. This year, such income was only ₹1.6 crore, impacting the year-over-year profit comparison. The company has concentrated on strengthening its core operations, particularly its Vitamin D3 business and expanding into green chemistry solutions.

Future Outlook

Investors can expect Fermenta Biotech to continue focusing on operational performance and growth drivers within its specific segments. The recommended dividend offers a direct return to shareholders. The company is positioning itself for further expansion in its nutrition and green chemistry businesses.

Areas of Concern

• Animal Nutrition Pricing: A 16% decrease in average realization for animal nutrition, despite volume growth, suggests potential pricing pressures in this segment.
• US Subsidiary Operations: The increased EBITDA loss in the US trading business indicates ongoing operational challenges that require management attention.
• Profitability Interpretation: Investors will need to differentiate between core operational performance and one-time income when assessing overall profitability.

Segment-Specific Results

• Vitamin D3 - Human Nutrition: Revenue grew 28% to ₹292.7 crore, with human nutrition volumes up 21% year-over-year.
• Vitamin D3 - Animal Nutrition: Revenue increased 32% to ₹108.5 crore. Volumes rose 49% year-over-year, but average realization fell 16% year-over-year.
• Other APIs and Intermediates: Revenue grew 27% to ₹47.6 crore.
• Green Chemistry Solutions: Revenue more than doubled, increasing 126% to ₹15.9 crore.
• Environmental Solutions: Revenue declined 14% to ₹19.2 crore.

Subsidiary Performance Highlights

• German Toll Manufacturing: Revenue increased 101% to ₹76.6 crore, though EBITDA fell 18% to ₹11.3 crore.
• US Trading Business: Revenue decreased 10% to ₹45.2 crore, with the EBITDA loss widening to ₹1.9 crore from ₹0.5 crore.

Key Metrics Overview

Next Steps for Investors

Investors should track the volume growth and pricing trends in both human and animal nutrition segments. The scalability of the Green Chemistry Solutions business and any recovery efforts for the US trading subsidiary will also be key areas to watch.